Biomaterial catheters help avoid common vascular access complications, delivering improved patient outcomes and a lower cost of careBILLERICA, Mass., Dec....
Company Provides Comprehensive Clinical Update from Phase 1/2 TrialTuspetinib Continues to Deliver Single Agent Responses in r/r AML PatientsTuspetinib Safety...
– ASH poster presentation summarizes preclinical data from SENTI-202, an off-the-shelf CAR-NK cell therapy candidate engineered with a logic-gated gene...
-- Preliminary study results show that tifcemalimab is well-tolerated at all administered doses. The observed clinical activity of tifcemalimab in...
Oral presentation at American Society of Hematology (ASH) Annual Meeting highlights continued favorable safety and tolerability profile and sustained long-term...
Updated MCL and CLL data from the ongoing Phase 1/2 study of zilovertamab and ibrutinib are encouraging and continue to...
Data from REDIRECT establish that AFM13 monotherapy is effective in the treatment of relapsed/refractory peripheral T cell lymphoma (r/r PTCL)...
Interim Phase 1 Data of FT576 BCMA-targeted Product Candidate Show Clinical Activity in Initial Single-dose Escalation Cohorts as Monotherapy and...
AFM13 in combination with NK cells shows very high overall and complete response rates in 41 heavily pre-treated CD30-positive Hodgkin...
Oral podium presentation highlights data demonstrating a 79% overall response rate and complete responses in 43% of relapsed or refractory...
Initial Phase 1b study results show clinical activity with immune-based triplet therapy regimen1 BEERSE, Belgium, Dec. 10, 2022 (GLOBE NEWSWIRE)...
With nearly four years of study follow-up, all-oral, fixed-duration IMBRUVICA® (ibrutinib) + venetoclax reduced the risk of progression or death...
Results from the pivotal MonumenTAL-1 study, including first results from the Phase 2 portion, featured at the 2022 ASH Annual...
First immune thrombocytopenia (ITP) plenary selection in 15 years underscores significant unmet need in this rare, serious autoimmune bleeding disease...
– 30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML –– Low frequency of differentiation syndrome,...
- A total of 17 pediatric patients were treated with STRO-002 on a compassionate use basis; eight patients achieved complete...
Poster presentation to include initial data from subcutaneous administration and updates on intravenous dosing-cohortsUTRECHT, The Netherlands and PHILADELPHIA, Pa., Dec....
-Participants with SR-aGVHD disease achieved an ORR of 67% and CR of 17% as measured by best response- -Participants with...
Multiple presentations reinforce clonoSEQ’s ability to provide valuable insights for treatment surveillance and clinical decision-makingMore than 30 clonoSEQ-related abstracts to...
FT819 Off-the-Shelf CAR T-cell Product Candidate Derived from Clonal Engineered Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into...